Abstract
The Stock Exchange of Thailand will list T.Man Pharmaceutical pcl. on October 22 under the symbol “TMAN” with a market capitalization of THB 6.52 billion. TMAN specializes in pharmaceutical and healthcare products, offering a diverse portfolio in four main categories. The company aims to innovate and expand its presence in the healthcare market with the capital raised from its IPO. The Thanachotipan family is the principal shareholder, and the company’s dividend policy is to distribute a minimum of 30 percent of net profit after tax.
SET to List T.Man Pharmaceutical pcl. on October 22
The Stock Exchange of Thailand (SET) will list T.Man Pharmaceutical pcl., a leading pharmaceutical and healthcare product distributor and manufacturer, on October 22 under the symbol “TMAN”. The company has a market capitalization at its initial public offering (IPO) of THB 6.52 billion (approx. USD 195.77 million). SET Executive Vice President Rungtip Charoenvisuthiwong said that TMAN will be listed and start trading on SET in the Consumer Products industry group, Personal Products and Pharmaceuticals sector.
TMAN: A Pioneer in Pharmaceutical and Healthcare Products
TMAN has established itself as a prominent manufacturer and distributor of pharmaceutical and healthcare products with a diverse portfolio spanning both OEM products and over 200 proprietary brands. The company’s offerings are divided into four main categories: generic drugs, herbal medicine, supplementary diets and cosmetics, and other healthcare products. TMAN has successfully captured consumer attention with several top-performing brands, including Propoliz, Iyara, Myda, IBUMAN, Polar, and Vita-C. The capital raised from the company’s IPO will be primarily directed towards production capacity upgrades to support TMAN’s business expansion and future growth.
